Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | ASCO 2019: CAR-T trial highlights

Nirav Niranjan Shah • 3 Jun 2019
ASCO 2019
Lymphoma Non-Hodgkin Lymphoma

In this video, Nirav Niranjan Shah, MD, highlights new, exciting CAR T-cell data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago, IL. The TRANSCEND-NHL-001 Phase I trial (NCT02631044) showed promise in mantle cell lymphoma, being effective against CNS disease.

More from Nirav Niranjan Shah

Updated data on bexobrutideg in Waldenström’s macroglobulinemia: an ongoing Phase Ia/b trial 2:11
Updated data on bexobrutideg in Waldenström’s macroglobulinemia: an ongoing Phase Ia/b trial
Nirav Niranjan Shah • 6 Dec 2025
Treating R/R DLBCL in 2025: CAR T-cell therapy and bispecific antibodies 2:07
Treating R/R DLBCL in 2025: CAR T-cell therapy and bispecific antibodies
Nirav Niranjan Shah • 6 Dec 2025
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL 3:05
Phase II trial of mosunetuzumab with response-driven lenalidomide augmentation in FL and MZL
Adam Olszewski • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals